Streptococcus Group ANCT00264784
GAS Epi Study to Measure Age-Related Antibody Titers to J8 Vaccine
An observational study of Streptococcus Group A, run by National Institute of Allergy and Infectious Diseases (NIAID) at 1 site in Fiji.
Trial summary
The purpose of this ongoing study (Part V) is to evaluate the cause, distribution, control, and results of group A streptococcus infections (GAS) in Fiji. Patients of all ages presenting to the Colonial War Memorial Hospital, Suva, Fiji and patients donating blood to the Colonial War Memorial Hospital, Suva, Fiji may… Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Streptococcus Group A
- How many people
- 300 participants
- Where
- 1 siteFiji
- Study dates
- Dec 2005to May 2006
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Individuals of any age who are inpatients or outpatients at Colonial War Memorial Hospital and provide informed consent.
Who cannot join
- Patients will be excluded from participating in the study if they have a history of acute rheumatic fever, acute post streptococcal glomerulonephritis, rheumatic heart disease, or invasive Group A Streptococcus disease or have had a sore throat or skin sores within the past 14 days as determined by self report, or if they have a current febrile illness (>38.0 degrees Celsius).
Trial locations and contacts
1 site in 1 country.
Fiji1 site
Colonial War Memorial Hospital
Suva
About this study
Official title: The Epidemiology of Group A Streptococcal Infections in Fiji (Fiji GrASP) - Part 5: Establishing Natural Age-Related Titers of Antibodies to the J8 Group A Streptococcal Epitope in Fiji
The purpose of this ongoing study (Part V) is to evaluate the cause, distribution, control, and results of group A streptococcus infections (GAS) in Fiji. Patients of all ages presenting to the Colonial War Memorial Hospital, Suva, Fiji and patients donating blood to the Colonial War Memorial Hospital, Suva, Fiji may participate. Subject duration is less than one day. This study may help to develop a vaccine that will prevent group A streptococcal infections.
Read the detailed description
Most group A streptococcus (GAS) disease occurs in childhood and the premise of this study is that with increasing age there is apparent clinical protection from GAS disease which is due to the acquisition of protective antibodies. The study therefore seeks to test the hypothesis that titers of anti-J8 antibodies will increase with increasing age. This study is part 5 of a series including Division of Microbiology and Infectious Diseases (DMID) protocols 05-0082, 05-0117, 05-0118, and 06-0081. Three hundred patients will be selected in 6 age groups with 50 patients in each group: 0-4 years of age, 5-14 years of age, 15-24 years of age, 25-34 years of age, 35-49 years of age, over 50 years of age. Participants will be recruited through the Colonial War Memorial (CWM) Hospital in Suva. Patients in the hospital who are having blood taken for reasons other than GAS disease will be approached and asked to participate in the study. These patients will include people who are donating blood to the blood collection service for CWM Hospital. In addition, it will include patients going to the operating room or patients having blood taken as an outpatient by the pathology blood collection service. Once informed consent is obtained, blood will be collected in a serum separator blood tube. The volume of blood required for age groups will vary: 3ml whole blood for those aged <5 years, 5 mls for those aged 5-14 years, 7.5 mls for those aged greater than 14 years. Participants will be excluded if they have a history of serious GAS disease including acute rheumatic fever, acute post streptococcal glomerulonephritis, invasive disease, or rheumatic heart disease, or if they have had a sore throat or skin sores within the past 14 days. These participants will be excluded because it is not known if J8 titres may correlate with prior serious GAS diseases or if there is an acute J8 antibody response to recent GAS infection, and we are aiming to understand background titres of J8 antibodies in this population. In addition, these illnesses will affect the value of antistreptolysin O titre (ASOT) and anti-DNase-B to establish the upper limits of normal values. After blood is centrifuged it will be divided. Aliquots will be prepared for measurement of ASOT and anti-DNase B titers. Further aliquots will be stored in the laboratory and sent to Queensland Institute of Medical Research in batch for measurement of J8 antibodies.
- Conditions
- Streptococcus Group A
- Keywords
- Streptococcus, Group A, Fiji, epidemiology
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Dec 2005 (estimated)
- Study startDec 2005
- Study completionMay 2006
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Streptococcus Group AStudies of the same condition, open and under way.
- More trials run by National Institute of Allergy and Infectious Diseases (NIAID)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Prospective
- Enrolment
- 300 participants
Sponsor and investigators
- Sponsor type
- US National Institutes of Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00264784
- Sponsor's protocol ID
- 05-0081
- Status last verified
- Oct 2007
- First submitted
- 9 Dec 2005
- Last updated
- 28 Dec 2007
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Dec 2007. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Epidemiology of Group A Streptococcal Infections in Fiji (Fiji GrASP) - Part 5: Establishing Natural Age-Related Titers of Antibodies to the J8 Group A Streptococcal Epitope in Fiji
- ClinicalTrials.gov ID
- NCT00264784
- Acronym / sponsor ID
- 05-0081
- Conditions
- Streptococcus Group A
- Keywords
- Streptococcus, Group A, Fiji, epidemiology
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 300 participants
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)US National Institutes of Health
- Study start
- Dec 2005
- Study completion
- May 2006
- First posted
- 13 Dec 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this ongoing study (Part V) is to evaluate the cause, distribution, control, and results of group A streptococcus infections (GAS) in Fiji. Patients of all ages presenting to the Colonial War Memorial Hospital, Suva, Fiji and patients donating blood to the Colonial War Memorial Hospital, Suva, Fiji may participate. Subject duration is less than one day. This study may help to develop a vaccine that will prevent group A streptococcal infections.
Detailed description
Most group A streptococcus (GAS) disease occurs in childhood and the premise of this study is that with increasing age there is apparent clinical protection from GAS disease which is due to the acquisition of protective antibodies. The study therefore seeks to test the hypothesis that titers of anti-J8 antibodies will increase with increasing age. This study is part 5 of a series including Division of Microbiology and Infectious Diseases (DMID) protocols 05-0082, 05-0117, 05-0118, and 06-0081. Three hundred patients will be selected in 6 age groups with 50 patients in each group: 0-4 years of age, 5-14 years of age, 15-24 years of age, 25-34 years of age, 35-49 years of age, over 50 years of age. Participants will be recruited through the Colonial War Memorial (CWM) Hospital in Suva. Patients in the hospital who are having blood taken for reasons other than GAS disease will be approached and asked to participate in the study. These patients will include people who are donating blood to the blood collection service for CWM Hospital. In addition, it will include patients going to the operating room or patients having blood taken as an outpatient by the pathology blood collection service. Once informed consent is obtained, blood will be collected in a serum separator blood tube. The volume of blood required for age groups will vary: 3ml whole blood for those aged <5 years, 5 mls for those aged 5-14 years, 7.5 mls for those aged greater than 14 years. Participants will be excluded if they have a history of serious GAS disease including acute rheumatic fever, acute post streptococcal glomerulonephritis, invasive disease, or rheumatic heart disease, or if they have had a sore throat or skin sores within the past 14 days. These participants will be excluded because it is not known if J8 titres may correlate with prior serious GAS diseases or if there is an acute J8 antibody response to recent GAS infection, and we are aiming to understand background titres of J8 antibodies in this population. In addition, these illnesses will affect the value of antistreptolysin O titre (ASOT) and anti-DNase-B to establish the upper limits of normal values. After blood is centrifuged it will be divided. Aliquots will be prepared for measurement of ASOT and anti-DNase B titers. Further aliquots will be stored in the laboratory and sent to Queensland Institute of Medical Research in batch for measurement of J8 antibodies.
Study design
- Time perspective
- Prospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- Individuals of any age who are inpatients or outpatients at Colonial War Memorial Hospital and provide informed consent.
Key exclusion criteria (1 listed)
- Patients will be excluded from participating in the study if they have a history of acute rheumatic fever, acute post streptococcal glomerulonephritis, rheumatic heart disease, or invasive Group A Streptococcus disease or have had a sore throat or skin sores within the past 14 days as determined by self report, or if they have a current febrile illness (>38.0 degrees Celsius).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Dec 2007.
Related trials for Streptococcus Group A
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
RecruitingObservational study
A Multicenter Evaluation of SalivIQ™ Strep A for Detecting Group A Streptococcus From Saliva and Throat Swabs in Patients With Acute Pharyngitis
Streptococcal Pharyngitis, Group A Streptococcal Infection
RecruitingPhase 3
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
Healthy
Not yet recruitingPhase 1
Stopping Strep Throat With Antibodies in Healthy Adults.
Streptococcal Pharyngitis
Active, not recruiting
Evaluation of Efficacy of Antibacterial Activity of Licorice, Clove, and Chlorohexidine Mouthwashes on Salivary Streptococcus Mutans in a Group of Egyptian Children.
Dental Caries, Streptococcal Infections
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Streptococcus Group A, run by National Institute of Allergy and Infectious Diseases (NIAID) at 1 site in Fiji.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Dec 2007. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Fiji. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Dec 2007.